CLNN Stock - Clene Inc.
Unlock GoAI Insights for CLNN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $342,000 | $654,000 | $473,000 | $723,000 | $206,000 |
| Gross Profit | $272,000 | $533,000 | $447,000 | $434,000 | $141,000 |
| Gross Margin | 79.5% | 81.5% | 94.5% | 60.0% | 68.4% |
| Operating Income | $-33,093,000 | $-40,540,000 | $-48,409,000 | $-49,978,000 | $-20,214,000 |
| Net Income | $-39,400,000 | $-49,504,000 | $-29,918,000 | $-9,740,000 | $-19,277,000 |
| Net Margin | -11520.5% | -7569.4% | -6325.2% | -1347.2% | -9357.8% |
| EPS | $-5.67 | $-9.43 | $-4.69 | $-3.16 | $-5.51 |
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Visit WebsiteEarnings History & Surprises
CLNNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 23, 2026 | $-0.74 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.60 | $-0.85 | -41.7% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-0.49 | $-0.78 | -59.2% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-1.10 | $-0.50 | +54.5% | ✓ BEAT |
Q1 2025 | Mar 24, 2025 | $-1.21 | $-1.67 | -38.0% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-1.34 | $-1.22 | +9.0% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-1.60 | $-1.06 | +33.8% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-1.80 | $-1.80 | 0.0% | = MET |
Q1 2024 | Mar 13, 2024 | $-1.40 | $-1.20 | +14.3% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-2.00 | $-0.40 | +80.0% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-2.60 | $-2.40 | +7.7% | ✓ BEAT |
Q2 2023 | May 12, 2023 | $-3.20 | $-3.00 | +6.3% | ✓ BEAT |
Q1 2023 | Mar 13, 2023 | $-3.00 | $-3.20 | -6.7% | ✗ MISS |
Q4 2022 | Nov 7, 2022 | $-4.60 | $-2.80 | +39.1% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-4.20 | $-4.40 | -4.8% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-3.60 | $-4.20 | -16.7% | ✗ MISS |
Q1 2022 | Mar 11, 2022 | $-3.60 | $-3.80 | -5.6% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-4.40 | $-0.60 | +86.4% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-2.00 | $-4.20 | -110.0% | ✗ MISS |
Q2 2021 | May 11, 2021 | $-1.80 | $-3.80 | -111.1% | ✗ MISS |
Latest News
D. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target
📈 PositiveD. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target
📈 PositiveCLNN stock has given up its prior gain. Clene shares were trading higher after the company announced it completed the FDA-recommended biomarker analyses for CNM-Au8 in people living with ALS.
➖ NeutralClene shares are trading higher after the company announced it completed the FDA-recommended biomarker analyses for CNM-Au8 in people living with ALS.
📈 PositiveClene Completes FDA-Recommended Biomarker Analyses For CNM-Au8 In Patients With Amyotrophic Lateral Sclerosis; Data Shows Reductions In Neurofilament Light, Glial Fibrillary Acidic Protein
📈 PositiveClene To Update Investors On CNM-Au8 ALS Program In December 3 Webcast At 8:30am ET
➖ NeutralD. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target
📈 PositiveClene Q3 EPS $(0.85) Misses $(0.58) Estimate, Sales $15.000K Miss $55.143K Estimate
📉 NegativeD. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target
📈 PositiveD. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target
📈 PositiveClene To Present At ECTRIMS 2025 Meeting Sept. 24-26
➖ NeutralBenchmark Maintains Buy on Clene, Lowers Price Target to $31
📈 PositiveClene Files Prospectus Supplement For $6.28M Shares
➖ NeutralClene Inc Announces New Preclinical Data Showing That Its Lead Candidate, CNM-Au8, Improved Cellular Health In A Dopaminergic Neuron Model Of Parkinson's Disease
📈 PositiveD. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target
📈 PositiveCanaccord Genuity Maintains Buy on Clene, Lowers Price Target to $48
➖ NeutralClene Posts 70% Revenue Drop in Q2
📉 NegativeFrequently Asked Questions about CLNN
What is CLNN's current stock price?
What is the analyst price target for CLNN?
What sector is Clene Inc. in?
What is CLNN's market cap?
Does CLNN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CLNN for comparison